Quilizumab
Based on 1 Customer Validation
Quilizumab (Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A) is a monoclonal antibody that targets FcγRIIIa and the M1 prime segment of human membrane-bound IgE. Quilizumab has enhanced FcγRIIIa binding affinity and activity against IgE class-switched B cells, and reduces serum IgE levels by inducing antibody-dependent cell-mediated cytotoxicity and apoptosis through cross-linking of membrane-bound IgE receptors. Quilizumab depletes IgE-producing cells; it also directly binds the membrane-bound M1 prime domain on IgE class-switched cells to inhibit IgE production. Quilizumab is used in research on allergic asthma and allergic diseases (asthma, allergic rhinitis).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.56%
- CAS No.: 1228538-47-3
- Masse moléculaire:146.5 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IGHE
In Vitro
Quilizumab (0.0051‑10000 ng/mL; 3 h) mediates potent ADCC activity against Daudi B cells transfected with membrane‑bound IgE, and its ADCC potency is approximately 10‑fold higher than that of the wild‑type anti‑M1 prime antibody[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Daudi human B lymphoma cells transfected with human membrane IgE
-
Concentration:0.001, 0.01, 0.1, 1, 10, 25 μg/mL
-
Incubation Time:72 h
-
Result:Induced apoptosis of target cells with no significant differences in maximal percent apoptosis or dose-response compared to the wildtype antibody.
In Vivo
Quilizumab inhibits the production of new allergen-specific IgE induced by allergen stimulation in biological model systems related to allergic asthma[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID-beige mice (sublethally irradiated with 3.5 Gy; reconstituted with human PBMCs)[1]
-
Dosage:3, 30, 300 μg
-
Administration:i.p.; days 0, 4, and 7
-
Result:Reduced human IgE in serum at all doses (3, 30, 300 μg) with maximal activity.
Exhibited approximately 100-fold higher potency than the wildtype counterpart, showing comparable activity at 1/100th the dose.
Did not affect human IgM levels.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- Ovalbumin-Induced Allergic Airway Inflammation
- Apoptosis Solutions
- Recombinant antibody expression and Protein A/G purification
- Cell Viability Determination by MTT Colorimetric Assay
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IgE Protein, Human (HEK293, His, HY-P73907) can bind Quilizumab. The EC50 for this effect is 486.8 ng/mL.
Chemical Information
-
CAS No. 1228538-47-3
-
Appearance Liquid
-
Masse moléculaire 146.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Quilizumab]
-
Synonyms
Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Quilizumab Related Classifications
HY-P99313 Related Classifications
Powered by Bioz
Keywords
- Quilizumab
- 1228538-47-3
- Anti-Human IGHE Recombinant Antibody
- 47H4
- MEMP1972A
- Drug Derivative
- Fc Receptor (FcR)
- Apoptosis
- Drug derivative
- Fc Receptor
- Daudi B cells
- FcγRIIIa
- allergic asthma
- allergic rhinitis
- IgE-switched B cells
- human membrane IgE
- apoptosis
- human PBMC-SCID mouse model
- M1 prime segment
- antibody-dependent cell-mediated cytotoxicity
- Inhibitor
- inhibitor
- inhibit